Novartis has struck a deal with Takeda that will allow the Swiss pharma giant entry into the world's third largest vaccine market.

Takeda has agreed to pay Novartis a little more than a million dollars upfront along with milestones and royalties for Vaxem-Hib, a vaccine for the Haemophilus influenza Type B (Hib). Takeda takes on responsibility for clinical trials in Japan and will file the NDA for the vaccine, which will be sold under the Novartis name.

Japan's vaccine market is valued at $640 million and is widely expected to grow more.

- read the report [1] from Reuters

Related Articles:
Novartis pays $20M up front for vax program [2]
Xoma, Novartis restructure vaccine agreement [3]
Novartis plans trials for growing vaccines pipeline [4]
Novartis eyes vaccines with Protez purchase [5]